Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 190, Issue 2, Pages 173-178Publisher
WILEY
DOI: 10.1111/bjh.16815
Keywords
myeloma therapy; cost benefit; health services research; COVID-19; telemedicine
Categories
Ask authors/readers for more resources
The pandemic has affected every aspect of myeloma care. Immediate focus is minimising risk of contracting coronavirus disease 2019 (COVID-19) and the sequelae of infection. However, what does the future hold for our patients? What lessons will be taken forward to tackle myeloma in the fiscally constrained future? If we embrace the challenges that will emerge in the post-pandemic environment, the treatment delivered to patients could be more cost-effective and better tailored than before. Healthcare delivery post-COVID-19 will not return to how it was, and now is the time to invest in novel strategies to deliver the best possible outcomes for patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available